Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position

Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.